{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T15:57:33Z","timestamp":1792684653044,"version":"4.5.0"},"reference-count":70,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82374445"],"award-info":[{"award-number":["82374445"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005892","name":"China Academy of Chinese Medical Sciences","doi-asserted-by":"publisher","award":["CI2023C018LH"],"award-info":[{"award-number":["CI2023C018LH"]}],"id":[{"id":"10.13039\/501100005892","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2024YFC3505301"],"award-info":[{"award-number":["2024YFC3505301"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017950","name":"Shanghai Municipal Health Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017950","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008750","name":"Shanghai Municipal Hospital Development Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008750","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.autrev.2026.104054","type":"journal-article","created":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T02:04:35Z","timestamp":1775181875000},"page":"104054","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Effects of biologics and small-molecule inhibitors on lipid profiles in patients with psoriasis or psoriatic arthritis: An analysis of current evidence"],"prefix":"10.1016","volume":"25","author":[{"given":"Miao","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengbo","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruiqing","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyu","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoce","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seokgyeong","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoying","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yonghua","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"19","key":"10.1016\/j.autrev.2026.104054_bb0005","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1001\/jama.2020.4006","article-title":"Pathophysiology, clinical presentation, and treatment of psoriasis: a review","volume":"323","author":"Armstrong","year":"2020","journal-title":"Jama"},{"issue":"6","key":"10.1016\/j.autrev.2026.104054_bb0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2024.103577","article-title":"Global prevalence of obesity in patients with psoriasis: an analysis in the past two decades","volume":"23","author":"Wang","year":"2024","journal-title":"Autoimmun Rev"},{"issue":"8","key":"10.1016\/j.autrev.2026.104054_bb0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.dsx.2024.103098","article-title":"Epidemiology of lipid disturbances in psoriasis: an analysis of trends from 2006 to 2023","volume":"18","author":"Zhang","year":"2024","journal-title":"Diabetes Metab Syndr"},{"issue":"11","key":"10.1016\/j.autrev.2026.104054_bb0020","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1111\/jdv.18296","article-title":"Global prevalence of metabolic syndrome in patients with psoriasis in the past two decades: current evidence","volume":"36","author":"Liu","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"11","key":"10.1016\/j.autrev.2026.104054_bb0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2025.103889","article-title":"Cardiovascular risk in psoriatic arthritis: how can we manage it?","volume":"24","author":"Atzeni","year":"2025","journal-title":"Autoimmun Rev"},{"issue":"1","key":"10.1016\/j.autrev.2026.104054_bb0030","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s40259-022-00569-z","article-title":"Biologic and small-molecule therapies for moderate-to-severe psoriasis: focus on psoriasis comorbidities","volume":"37","author":"Jiang","year":"2023","journal-title":"BioDrugs"},{"issue":"2","key":"10.1016\/j.autrev.2026.104054_bb0035","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics16020239","article-title":"New and emerging oral\/topical small-molecule treatments for psoriasis","volume":"16","author":"Carmona-Rocha","year":"2024","journal-title":"Pharmaceutics"},{"issue":"6","key":"10.1016\/j.autrev.2026.104054_bb0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2025.103819","article-title":"Janus kinase inhibitors for psoriatic arthritis: evidence from a systematic review and network meta-analysis","volume":"24","author":"Tsiogkas","year":"2025","journal-title":"Autoimmun Rev"},{"issue":"1","key":"10.1016\/j.autrev.2026.104054_bb0045","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s13555-024-01327-5","article-title":"Biologic therapy and cardiometabolic risk in psoriasis: a retrospective review","volume":"15","author":"Smith","year":"2025","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"9","key":"10.1016\/j.autrev.2026.104054_bb0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.jid.2020.01.025","article-title":"A randomized placebo-controlled trial of secukinumab on aortic vascular inflammation in moderate-to-severe plaque psoriasis (VIP-S)","volume":"140","author":"Gelfand","year":"2020","journal-title":"J Invest Dermatol"},{"issue":"7","key":"10.1016\/j.autrev.2026.104054_bb0055","article-title":"Biological anti-psoriatic therapy profoundly affects high-density lipoprotein function","volume":"1866","author":"Trakaki","year":"2021","journal-title":"Biochim Biophys Acta"},{"issue":"4","key":"10.1016\/j.autrev.2026.104054_bb0060","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1111\/ijd.70122","article-title":"Risk of dyslipidemia associated with oral janus kinase inhibitors: a systematic review and meta-analysis of randomized placebo-controlled trials","volume":"65","author":"Isufi","year":"2026","journal-title":"Int J Dermatol"},{"issue":"1","key":"10.1016\/j.autrev.2026.104054_bb0065","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1002\/art.38894","article-title":"Lipid profile changes in patients with chronic inflammatory arthritis treated with biologic agents and tofacitinib in randomized clinical trials: a systematic review and meta-analysis","volume":"67","author":"Souto","year":"2015","journal-title":"Arthritis Rheum"},{"issue":"10","key":"10.1016\/j.autrev.2026.104054_bb0070","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1136\/annrheumdis-2015-207872","article-title":"Comparison of lipid and lipid-associated cardiovascular risk marker changes after treatment with tocilizumab or adalimumab in patients with rheumatoid arthritis","volume":"75","author":"Gabay","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.autrev.2026.104054_bb0075","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.114.001588","article-title":"The association between reduction in inflammation and changes in lipoprotein levels and HDL cholesterol efflux capacity in rheumatoid arthritis","volume":"4","author":"Liao","year":"2015","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.autrev.2026.104054_bb0080","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1254753","article-title":"Dyslipidemia in rheumatoid arthritis: the possible mechanisms","volume":"14","author":"Yan","year":"2023","journal-title":"Front Immunol"},{"issue":"12","key":"10.1016\/j.autrev.2026.104054_bb0085","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.1161\/ATVBAHA.124.319983","article-title":"Immune-mediated inflammatory diseases, dyslipidemia, and cardiovascular risk: a complex interplay","volume":"44","author":"Wilkinson","year":"2024","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"8","key":"10.1016\/j.autrev.2026.104054_bb0090","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1038\/s41584-019-0256-0","article-title":"Cardiometabolic comorbidities in RA and PsA: lessons learned and future directions","volume":"15","author":"Ferguson","year":"2019","journal-title":"Nat Rev Rheumatol"},{"issue":"3","key":"10.1016\/j.autrev.2026.104054_bb0095","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1080\/09546634.2016.1214666","article-title":"The effect of low-carbohydrates calorie-restricted diet on visceral adipose tissue and metabolic status in psoriasis patients receiving TNF-alpha inhibitors: results of an open label controlled, prospective, clinical study","volume":"28","author":"Campanati","year":"2017","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.autrev.2026.104054_bb0100","doi-asserted-by":"crossref","first-page":"35","DOI":"10.5336\/dermato.2020-74503","article-title":"Impact of treatment with methotrexate and TNF alpha Inhibitors on insulin resistance in patients with psoriasis","volume":"30","author":"Demir","year":"2020","journal-title":"Turk Klin Dermatol"},{"issue":"4","key":"10.1016\/j.autrev.2026.104054_bb0105","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1093\/cvr\/cvz009","article-title":"Coronary artery plaque characteristics and treatment with biologic therapy in severe psoriasis: results from a prospective observational study","volume":"115","author":"Elnabawi","year":"2019","journal-title":"Cardiovasc Res"},{"issue":"4","key":"10.1016\/j.autrev.2026.104054_bb0110","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1111\/bjd.12118","article-title":"Serum chemerin is increased in patients with chronic plaque psoriasis and normalizes following treatment with infliximab","volume":"168","author":"Gisondi","year":"2013","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.autrev.2026.104054_bb0115","doi-asserted-by":"crossref","first-page":"14","DOI":"10.23736\/S0392-0488.17.05621-8","article-title":"Effects of TNF\u03b1 inhibitors in patients with psoriasis and metabolic syndrome: a preliminary study","volume":"155","author":"Merlo","year":"2020","journal-title":"G Ital Dermatol Venereol"},{"issue":"1","key":"10.1016\/j.autrev.2026.104054_bb0120","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-88552-6","article-title":"AntiTNF-alpha therapy normalizes levels of lipids and adipokines in psoriatic patients in the real-life settings","volume":"11","author":"Olejniczak-Staruch","year":"2021","journal-title":"Sci Rep"},{"issue":"6","key":"10.1016\/j.autrev.2026.104054_bb0125","first-page":"661","article-title":"Efficacy of food supplement to improve metabolic syndrome parameters in patients affected by moderate to severe psoriasis during anti-TNF\u03b1 treatment","volume":"148","author":"Skroza","year":"2013","journal-title":"G Ital Dermatol Venereol"},{"issue":"9","key":"10.1016\/j.autrev.2026.104054_bb0130","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1111\/1346-8138.14526","article-title":"Effects of tumor necrosis factor-\u03b1, interleukin-23 and interleukin-17A inhibitors on bodyweight and body mass index in patients with psoriasis","volume":"45","author":"Takamura","year":"2018","journal-title":"J Dermatol"},{"issue":"10","key":"10.1016\/j.autrev.2026.104054_bb0135","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1111\/jdv.12296","article-title":"Initiation of TNF inhibitor therapy and change in physiologic measures in psoriasis","volume":"28","author":"Wu","year":"2014","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.autrev.2026.104054_bb0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.micpath.2021.105308","article-title":"Effectiveness and safety of adalimumab in psoriasis and its influence on gut microbiome","volume":"162","author":"Zhao","year":"2022","journal-title":"Microb Pathog"},{"issue":"3","key":"10.1016\/j.autrev.2026.104054_bb0145","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.orcp.2023.05.004","article-title":"Impact of biologic agents on body weight and obesity-related disorders in patients with psoriasis: a nationwide population-based cohort study","volume":"17","author":"Kim","year":"2023","journal-title":"Obes Res Clin Pract"},{"issue":"6","key":"10.1016\/j.autrev.2026.104054_bb0150","article-title":"Effect of 2 psoriasis treatments on vascular inflammation and novel inflammatory cardiovascular biomarkers: a randomized placebo-controlled trial","volume":"11","author":"Mehta","year":"2018","journal-title":"Circ Cardiovasc Ima"},{"issue":"5","key":"10.1016\/j.autrev.2026.104054_bb0155","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/j.jacl.2017.06.012","article-title":"Effect of tofacitinib on lipid levels and lipid-related parameters in patients with moderate to severe psoriasis","volume":"11","author":"Wolk","year":"2017","journal-title":"J Clin Lipidol"},{"issue":"6","key":"10.1016\/j.autrev.2026.104054_bb0160","doi-asserted-by":"crossref","first-page":"470","DOI":"10.3109\/09546634.2013.848260","article-title":"Cardiometabolic biomarkers in chronic plaque psoriasis before and after etanercept treatment","volume":"25","author":"Puig","year":"2014","journal-title":"J Dermatolog Treat"},{"issue":"8","key":"10.1016\/j.autrev.2026.104054_bb0165","doi-asserted-by":"crossref","first-page":"703","DOI":"10.36849\/JDD.2020.5337","article-title":"The effect of tildrakizumab on cardiometabolic risk factors in psoriasis by metabolic syndrome status: post hoc analysis of two phase 3 trials (ReSURFACE 1 and ReSURFACE 2)","volume":"19","author":"Menter","year":"2020","journal-title":"J Drugs Dermatol"},{"issue":"1","key":"10.1016\/j.autrev.2026.104054_bb0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaad.2018.02.074","article-title":"Ixekizumab treatment shows a neutral impact on cardiovascular parameters in patients with moderate-to-severe plaque psoriasis: results from UNCOVER-1, UNCOVER-2, and UNCOVER-3","volume":"79","author":"Egeberg","year":"2018","journal-title":"J Am Acad Dermatol"},{"issue":"9","key":"10.1016\/j.autrev.2026.104054_bb0175","first-page":"570","article-title":"Changes in body mass index and lipid profile in psoriatic patients after treatment with standard protocol of infliximab","volume":"54","author":"Ehsani","year":"2016","journal-title":"Acta Med Iran"},{"issue":"5","key":"10.1016\/j.autrev.2026.104054_bb0180","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/j.jaad.2016.06.012","article-title":"Effects of tofacitinib on cardiovascular risk factors and cardiovascular outcomes based on phase III and long-term extension data in patients with plaque psoriasis","volume":"75","author":"Wu","year":"2016","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.autrev.2026.104054_bb0185","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1111\/jdv.16004","article-title":"Effects of secukinumab on metabolic and liver parameters in plaque psoriasis patients","volume":"34","author":"Gerdes","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"10.1016\/j.autrev.2026.104054_bb0190","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1111\/j.1365-2133.2012.11168.x","article-title":"Efficacy and safety of tofacitinib, an oral janus kinase inhibitor, in the treatment of psoriasis: a phase 2b randomized placebo-controlled dose-ranging study","volume":"167","author":"Papp","year":"2012","journal-title":"Br J Dermatol"},{"issue":"2","key":"10.1016\/j.autrev.2026.104054_bb0195","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1111\/jdv.16635","article-title":"Disparate effects of adalimumab and fumaric acid esters on cardiovascular risk factors in psoriasis patients: results from a prospective, randomized, observer-blinded head-to-head trial","volume":"35","author":"Holzer","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"10.1016\/j.autrev.2026.104054_bb0200","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1007\/s40744-022-00434-z","article-title":"Effect of secukinumab on traditional cardiovascular risk factors and inflammatory biomarkers: post hoc analyses of pooled data across three indications","volume":"9","author":"Merola","year":"2022","journal-title":"Rheumatol Ther"},{"issue":"6","key":"10.1016\/j.autrev.2026.104054_bb0205","article-title":"Anti-interleukin-17 therapy of severe psoriatic patients results in an improvement of serum lipid and inflammatory parameters\u2019 levels, but has no effect on body composition parameters","volume":"11","author":"Piros","year":"2021","journal-title":"Life Basel"},{"issue":"5","key":"10.1016\/j.autrev.2026.104054_bb0210","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1111\/bjd.12144","article-title":"Oxidative stress and psoriasis: the effect of antitumour necrosis factor-\u03b1 inhibitor treatment","volume":"168","author":"Bacchetti","year":"2013","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.autrev.2026.104054_bb0215","doi-asserted-by":"crossref","first-page":"e30","DOI":"10.1111\/j.1468-3083.2012.04450.x","article-title":"Metabolic abnormalities associated with initiation of systemic treatment for psoriasis: evidence from the italian psocare registry","volume":"27","author":"Gisondi","year":"2013","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5","key":"10.1016\/j.autrev.2026.104054_bb0220","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1093\/bjd\/ljae014","article-title":"Deucravacitinib in plaque psoriasis: 2-year safety and efficacy results from the phase III POETYK trials","volume":"190","author":"Lebwohl","year":"2024","journal-title":"Br J Dermatol"},{"issue":"4","key":"10.1016\/j.autrev.2026.104054_bb0225","doi-asserted-by":"crossref","first-page":"332","DOI":"10.3109\/09546634.2015.1115819","article-title":"A randomized, double-blind, placebo-controlled, dose-escalation study of the safety and efficacy of INCB039110, an oral janus kinase 1 inhibitor, in patients with stable, chronic plaque psoriasis","volume":"27","author":"Bissonnette","year":"2016","journal-title":"J Dermatolog Treat"},{"issue":"1","key":"10.1016\/j.autrev.2026.104054_bb0230","doi-asserted-by":"crossref","first-page":"113","DOI":"10.5114\/ada.2023.135605","article-title":"Effects of secukinumab combined with tretinoin on metabolism, liver enzymes, and inflammatory factors in patients with moderate to severe psoriasis vulgaris","volume":"41","author":"Chen","year":"2024","journal-title":"Postepy Dermatol Alergol"},{"issue":"5","key":"10.1016\/j.autrev.2026.104054_bb0235","doi-asserted-by":"crossref","DOI":"10.3390\/jcm12051934","article-title":"Effects of biologic therapy on laboratory indicators of cardiometabolic diseases in patients with psoriasis","volume":"12","author":"Hagino","year":"2023","journal-title":"J Clin Med"},{"issue":"6","key":"10.1016\/j.autrev.2026.104054_bb0240","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1684\/ejd.2011.1548","article-title":"Effects of etanercept treatment on lipid profile in patients with moderate-to-severe chronic plaque psoriasis: a retrospective cohort study","volume":"21","author":"Lestre","year":"2011","journal-title":"Eur J Dermatol"},{"issue":"Supplement 10","key":"10.1016\/j.autrev.2026.104054_bb0245","article-title":"Changes in lipid levels and incidence of cardiovascular events following tofacitinib treatment in patients with psoriatic arthritis: an integrated analysis across phase 3 and long-term extension studies","volume":"69","author":"Gladman","year":"2017","journal-title":"Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.autrev.2026.104054_bb0250","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.jbspin.2014.02.005","article-title":"Atherosclerosis progression in psoriatic arthritis patients despite the treatment with tumor necrosis factor-alpha blockers: a two-year prospective observational study","volume":"81","author":"Ramonda","year":"2014","journal-title":"Joint Bone Spine"},{"issue":"12","key":"10.1016\/j.autrev.2026.104054_bb0255","first-page":"2440","article-title":"Modest but sustained increase of serum high density lipoprotein cholesterol levels in patients with inflammatory arthritides treated with infliximab","volume":"33","author":"Spanakis","year":"2006","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2026.104054_bb0260","doi-asserted-by":"crossref","DOI":"10.1155\/2011\/352686","article-title":"Infliximab induces increase in triglyceride levels in psoriatic arthritis patients","volume":"2011","author":"Castro","year":"2011","journal-title":"Clin Dev Immunol"},{"issue":"3","key":"10.1016\/j.autrev.2026.104054_bb0265","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1007\/s40744-020-00209-4","article-title":"Safety and efficacy of tofacitinib in patients with active psoriatic arthritis: interim analysis of OPAL balance, an open-label, long-term extension study","volume":"7","author":"Nash","year":"2020","journal-title":"Rheumatol Ther"},{"issue":"10","key":"10.1016\/j.autrev.2026.104054_bb0270","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.3899\/jrheum.201204","article-title":"Treatment with tofacitinib in refractory psoriatic arthritis: a national multicenter study of the first 87 patients in clinical practice","volume":"48","author":"Gal\u00edndez-Agirregoikoa","year":"2021","journal-title":"J Rheumatol"},{"issue":"3","key":"10.1016\/j.autrev.2026.104054_bb0275","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1007\/s10067-021-06003-z","article-title":"Effect of JAK inhibitors on high- and low-density lipoprotein in patients with rheumatoid arthritis: a systematic review and network meta-analysis","volume":"41","author":"Li","year":"2022","journal-title":"Clin Rheumatol"},{"issue":"2","key":"10.1016\/j.autrev.2026.104054_bb0280","doi-asserted-by":"crossref","DOI":"10.1111\/jdv.20184","article-title":"Arrhythmias and other cardiovascular diseases in young patients (<40years) with moderate\/severe atopic dermatitis: a multicentric study in northern Italy","volume":"39","author":"Paolino","year":"2025","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"10.1016\/j.autrev.2026.104054_bb0285","article-title":"Serum lipids alterations in patients under systemic JAK inhibitors treatments in dermatology","volume":"61","author":"Paolino","year":"2025","journal-title":"Clin Aspects Manage Med (Kaunas)"},{"issue":"3","key":"10.1016\/j.autrev.2026.104054_bb0290","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1080\/25785826.2023.2172808","article-title":"JAK inhibitors in rheumatology","volume":"46","author":"Yamaoka","year":"2023","journal-title":"Immunol Med"},{"issue":"2","key":"10.1016\/j.autrev.2026.104054_bb0295","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/ijd.15605","article-title":"TYK 2 inhibitors for the treatment of dermatologic conditions: the evolution of JAK inhibitors","volume":"61","author":"Jo","year":"2022","journal-title":"Int J Dermatol"},{"issue":"5","key":"10.1016\/j.autrev.2026.104054_bb0300","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1007\/s13555-021-00596-8","article-title":"Selectivity profile of the tyrosine kinase 2 inhibitor deucravacitinib compared with janus kinase 1\/2\/3 inhibitors","volume":"11","author":"Chimalakonda","year":"2021","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"502","key":"10.1016\/j.autrev.2026.104054_bb0305","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaw1736","article-title":"Autoimmune pathways in mice and humans are blocked by pharmacological stabilization of the TYK2 pseudokinase domain","volume":"11","author":"Burke","year":"2019","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.autrev.2026.104054_bb0310","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.curtheres.2018.07.001","article-title":"Effects of treatment with adalimumab on blood lipid levels and atherosclerosis in patients with rheumatoid arthritis","volume":"89","author":"Bergstr\u00f6m","year":"2018","journal-title":"Curr Ther Res Clin Exp"},{"issue":"6","key":"10.1016\/j.autrev.2026.104054_bb0315","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1136\/annrheumdis-2011-201148","article-title":"Effect of TNF inhibitors on lipid profile in rheumatoid arthritis: a systematic review with meta-analysis","volume":"71","author":"Da\u00efen","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2026.104054_bb0320","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1354593","article-title":"Effects of tumor necrosis factor-alpha inhibitors on lipid profiles in patients with psoriasis: a systematic review and meta-analysis","volume":"15","author":"Su","year":"2024","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.autrev.2026.104054_bb0325","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1186\/s13075-016-1148-1","article-title":"Effects of anti-TNF-\u03b1 treatment on lipid profile in rheumatic diseases: an analytical cohort study","volume":"18","author":"Hassan","year":"2016","journal-title":"Arthritis Res Ther"},{"issue":"2","key":"10.1016\/j.autrev.2026.104054_bb0330","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.ijcard.2006.12.032","article-title":"Effect of niacin on LXRalpha and PPARgamma expression and HDL-induced cholesterol efflux in adipocytes of hypercholesterolemic rabbits","volume":"124","author":"Zhao","year":"2008","journal-title":"Int J Cardiol"},{"issue":"1","key":"10.1016\/j.autrev.2026.104054_bb0335","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.jaad.2019.07.103","article-title":"Change in body weight and body mass index in psoriasis patients receiving biologics: a systematic review and network meta-analysis","volume":"82","author":"Wu","year":"2020","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.autrev.2026.104054_bb0340","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21030859","article-title":"The roles of lipoprotein in psoriasis","volume":"21","author":"Shih","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"2","key":"10.1016\/j.autrev.2026.104054_bb0345","doi-asserted-by":"crossref","first-page":"73","DOI":"10.3109\/07853890.2013.874661","article-title":"Lipid profile changes in patients with rheumatic diseases receiving a treatment with TNF-\u03b1 blockers: a meta-analysis of prospective studies","volume":"46","author":"Di Minno","year":"2014","journal-title":"Ann Med"},{"issue":"3","key":"10.1016\/j.autrev.2026.104054_bb0350","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1007\/s00394-013-0599-2","article-title":"TNF\u03b1 blockade for inflammatory rheumatic diseases is associated with a significant gain in android fat mass and has varying effects on adipokines: a 2-year prospective study","volume":"53","author":"Toussirot","year":"2014","journal-title":"Eur J Nutr"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997226000686?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997226000686?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T15:17:09Z","timestamp":1777130229000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997226000686"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":70,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S1568997226000686"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2026.104054","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effects of biologics and small-molecule inhibitors on lipid profiles in patients with psoriasis or psoriatic arthritis: An analysis of current evidence","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2026.104054","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104054"}}